> If you want that first time to be with prior immunity get vaccinated as that is the only known way to get immunity before your first infection.
Not disagreeing with your general point, but this statement is not accurate. For example, cross-reactive antibodies from other common cold coronaviruses can provide immune protection [1], which may partially explain why a large fraction of people are completely asymptomatic after initial SARS-COV-2 infection.
> COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2 but binding antibodies are also detected in prepandemic individuals, indicating potential crossreactivity with common cold human coronaviruses (HCoV) [1]
> In our study, we speculate that preexisting OC43 HCoV IgGs to N protein could be protective and, as a result, incoming SARS-CoV-2 infections would be more controlled and thus fewer antibodies induced against them.
> In conclusion, N protein is a primary target of SARS-CoV-2-specific and HCoV crossreactive antibodies, both of which may affect the acquisition of immunity to COVID-19. [1]
[1] Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879156/
Not disagreeing with your general point, but this statement is not accurate. For example, cross-reactive antibodies from other common cold coronaviruses can provide immune protection [1], which may partially explain why a large fraction of people are completely asymptomatic after initial SARS-COV-2 infection.
> COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2 but binding antibodies are also detected in prepandemic individuals, indicating potential crossreactivity with common cold human coronaviruses (HCoV) [1]
> In our study, we speculate that preexisting OC43 HCoV IgGs to N protein could be protective and, as a result, incoming SARS-CoV-2 infections would be more controlled and thus fewer antibodies induced against them.
> In conclusion, N protein is a primary target of SARS-CoV-2-specific and HCoV crossreactive antibodies, both of which may affect the acquisition of immunity to COVID-19. [1]
[1] Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879156/